AF
NGNE icon

Amalgamated Financial’s Neurogene NGNE Stock Holding History

Amalgamated Financial’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$9K Buy
+231
New +$13.5K ﹤0.01% 2912

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Amalgamated Financial's NGNE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Neurogene (NGNE) in Q1 2022: 231 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #2912 among its holdings.

81 funds tracked by Wall St. Rank hold NGNE as of Q1 2022.

  • Amalgamated Financial held 231 shares of Neurogene worth $9K as of Q1 2022.
  • Neurogene was a new Amalgamated Financial position in Q1 2022.
  • Neurogene made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2912 holding.
  • 81 funds tracked by Wall St. Rank held Neurogene as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.